Aims: Our research focuses on exploring the staging risk factors and genome sequence features that influence cardiovascular-renal-metabolic syndrome (CKM). Our goal is to screen high-risk populations for multidimensional risk factors, as well as to develop new screening metrics for different CKM staging to facilitate risk stratification and prognostication so that timely interventions and treatments can be implemented.
Scientific rationale: Cardiovascular, renal and metabolic diseases have long been a major global public health challenge due to their high prevalence and mortality rates, as well as the enormous economic burden they impose on society. The American Heart Association (AHA) has proposed a new conceptual framework for chronic kidney disease (CKD) that aims to enhance the comprehensive and longitudinal management of CKD. Despite the growing understanding of these diseases, their etiology, pathogenesis and prognosis remain to be fully elucidated. The aim of this proposal is to analyze multidimensional risk factors associated with CKM using high quality data from the UK Biobank. The identification of risk factors, including genome sequence data, is expected to improve understanding of the pathophysiology of CKM and contribute to the development of more effective prevention and treatment strategies.
Project duration: This project is expected to last for 36 months.
Public health impact: This study aims to identify the risk factors associated with the development of these diseases and hopes to screen high-risk populations and obtain new screening indicators. It is expected that clinical decision guidance for treatment planning will help to reduce the economic burden on society and make a significant contribution to the field of public health.